Starmab Biopharma Completes Tens of Millions RMB Series A+ Financing; Start Capital Acts as Financial Advisor for Subsequent Rounds

Recently,Beijing StarMab BioMed Technology Ltd. (referred to as: StarMab BioMed) announced the completion of a multi-million RMB A+ round of financing.. This round of financing was led byZhuhai Technology Venture Investment Co., Ltd., Zhuhai High tech Financial Investment Co., Ltd., and Start Capital jointly invested.，Start CapitalAct as the financial advisor for subsequent rounds of financing.

Before this round of financing, StarMab BioMed had already received investments from well-known domestic institutions such asAethan Capital, CICC Capital, Huajin Capital, Chang'an Private CapitalFavor. 

StarMab BioMed was founded inIn 2019, located in Beijing Zhongguan Village Life Science Park, it is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs. Based on its proprietary VHH multi-antibody biologic drug platform technology, it focuses on breakthrough indications that currently lack treatment options, developing global First-in-Class and Best-in-Class innovative multifunctional antibody drugs, as well as clinical research and commercialization worldwide.

Its industry-leading VHH antibody discovery platform ensures efficient generation and screening of VHH antibodies to obtain VHH antibody candidates with high affinity and high bioactivity. Its proprietary antibody engineering optimization platform effectively addresses issues related to antibody stability, immunogenicity, half-life, and manufacturability.The uniquely structured VHH multi-antibody molecules exhibit high-affinity targeted binding and synergistic effects; adjustable half-life; and mediate ADCC and ADCP.Characterized by a simple structure, small molecular weight, high expression level, high purification recovery rate, and good stability.

Currently,StarMab BioMed has developed a series of novel biologics with independent intellectual property rights, multipleFirst-in-class multifunctional antibody biologics are currently in the early stages of clinical trials in both China and the United States.Among them, SM3321 has been approved for IND in both China and the United States, and Phase I clinical trials have commenced. Preclinical data demonstrate excellent anti-tumor efficacy and safety. Its unique structural design enables high-affinity targeting and binding to multiple tumor sites while activating immune cell functions, achieving specific killing of tumor cells while minimizing non-specific toxic reactions to the greatest extent possible.

StarMab BioMed's technology in antibody production is also widely recognized in the industry. Using traditional CHO antibody production and purification processes, it can achieve industrial-scale production levels.

The other day, StarMab BioMed has obtainedLonza’s XS® Pichia Yeast Expression Production System Authorization Can Greatly Simplify the Production and Purification Process of VHH Antibodies, Achieving a Significant Reduction in Production Time and Cost While Ensuring Antibody Bioactivity and Yield.

Start CapitalStart Capital is a boutique investment bank focused on the healthcare and life sciences sectors, headquartered in Shanghai. The core team members of Start Capital come from top-tier medical and financial institutions both domestically and internationally, possessing forward-thinking international perspectives and outstanding experience in investment, entrepreneurship, operational management, and corporate governance. Relying on a comprehensive healthcare ecosystem and extensive capital market resources, Start Capital connects capital with enterprises, empowering medical technology companies by providing a series of value-added services such as equity financing, strategic planning, and post-investment management, accompanying every client served to embark on a new starting point.